US Patent Issued to Vaderis Therapeutics on Nov. 11 for "Allosteric AKT inhibitors for use in the treatment of Hereditary Hemorrhagic Telangiectasia" (Swiss Inventors)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,466,839, issued on Nov. 11, was assigned to Vaderis Therapeutics AG (Basel, Switzerland).

"Allosteric AKT inhibitors for use in the treatment of Hereditary Hemorrhagic Telangiectasia" was invented by Damien Picard (Basel, Switzerland) and Pierre Saint-Mezard (Basel, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, for use in the treatment of Hereditary Hemorrhagic Telangiectasia (HHT)."

The patent was filed on Sept. 29, 2021, under Application No. 18/247,261.

*For further information, including images, charts and tables, please visit: http:/...